Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05355597 · ClinicalTrials.gov registry record · Phase 2
"The Efficacy of Exparel Versus a Multidrug Cocktail in Soft Tissue Tumors"
A Phase 2 study, sponsored by Atlantic Health System.
- Terminated
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
NCT05355597 is a Phase 2 study that was terminated before completion, run by Atlantic Health System. The registered enrollment target is 116 participants.
The verdict
NCT05355597, a Phase 2 study, was terminated before completion, sponsored by Atlantic Health System.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
Study Summary
The objective of this proposed project is to determine which local anesthetic is more efficacious for use in soft tissue tumors: Exparel (liposomal bupivacaine) or a cocktail of Ropivicaine, Epinepherine, Ketolorac and Clonidine. This study will examine patients' post-operative pain levels as well as their narcotic consumption after removal of a soft tissue tumor while hospitalized and then twice daily through postoperative day 14.
Interventions
- DRUG Exparel Injectable Product
- DRUG Multi-Drug Cocktail (Ropivicaine, Epinephrine, Ketolorac, Clonidine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2021-01-27 |
| Est. Completion | 2025-03-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05355597
The ClinicalTrials.gov registry entry for NCT05355597 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atlantic Health System, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exparel Injectable Product is the first listed.
NCT05355597 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05355597 about?
NCT05355597 is a clinical study titled ""The Efficacy of Exparel Versus a Multidrug Cocktail in Soft Tissue Tumors"". The objective of this proposed project is to determine which local anesthetic is more efficacious for use in soft tissue tumors: Exparel (liposomal bupivacaine) or a cocktail of Ropivicaine, Epinepherine, Ketolorac and Clonidine. This study will examine patients' post-operative pain levels as well a...
What is the current status of trial NCT05355597?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2021-01-27. Estimated completion is 2025-03-24.
What interventions are being tested in trial NCT05355597?
The interventions under investigation include: Exparel Injectable Product (DRUG), Multi-Drug Cocktail (Ropivicaine, Epinephrine, Ketolorac, Clonidine) (DRUG).
Who is sponsoring clinical trial NCT05355597?
This trial is sponsored by Atlantic Health System, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.